http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105997978-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-26 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-295 |
filingDate | 2016-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-105997978-B |
titleOfInvention | Metal organic framework compound anti-tumor angiogenesis agent and using method thereof |
abstract | The invention provides a new application of an iron-metal organic framework compound (Fe-MIL-101), which discovers the anti-angiogenesis effect of Fe-MIL-101 for the first time, and discovers that Fe-MIL-101 can effectively inhibit the proliferation, migration and tubule formation of vascular endothelial cells for the first time, so that Fe-MIL-101 has anti-angiogenesis activity and can be used as an angiogenesis inhibitor. And Fe-MIL-101 has low toxicity to normal cells, and can be used as a selective angiogenesis inhibitor. |
priorityDate | 2016-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 199.